COMMUNIQUÉS West-GlobeNewswire

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

28/02/2025 - 15:00

One poster will share pooled INTEGUMENT data of ZORYVE ® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments [...]

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28/02/2025 - 15:00

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx ® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III REMIX pivotal [...]

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

28/02/2025 - 15:08

– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster presentations to [...]

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

28/02/2025 - 15:14

All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of [...]

Orion Corporation: Managers’ transactions – Niclas Lindstedt

28/02/2025 - 16:00

ORION CORPORATION MANAGERS’ TRANSACTIONS 28 FEBRUARY 2025 at 17.00 EET Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

28/02/2025 - 16:34

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Spectral AI, Inc. (NASDAQ: MDAI), the reporting date of the financial results for the fourth quarter was incorrectly [...]

SRx Health Solutions Granted Final Order to Proceed with the Acquisition by Better Choice Company

28/02/2025 - 16:41

TAMPA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced today that SRx Health Solutions, Inc. (“ [...]

Orion Corporation: Managers’ transactions – Outi Vaarala

28/02/2025 - 16:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 28 FEBRUARY 2025 at 17.45 EET Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

28/02/2025 - 17:14

First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX [...]

Valneva reçoit un avis positif du CHMP de l’EMA pour élargir l’indication de son vaccin contre le chikungunya IXCHIQ® aux adolescents

28/02/2025 - 17:45

Si l’avis est validé par la Commission Européenne, IXCHIQ ® pourrait devenir le premier vaccin contre le chikungunya disponible en Europe pour les adolescents âgés de 12 ans et plus Saint Herblain (France), le 28 [...]

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

28/02/2025 - 17:45

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – Valneva SE (Nasdaq: [...]

Groupe PAT : Hausse du Chiffre d’Affaires Combiné 2024

28/02/2025 - 18:30

Vandœuvre-lès-Nancy, le 28 février 2025 - 18 : 30 (CET) Communiqué de presse Pour diffusion immédiate Hausse du Chiffre d’Affaires Combiné 2024 Chiffre d’affaires combiné non audité en progression à 2,9 M€ (+26%/2023) [...]

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

28/02/2025 - 19:17

Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies. The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood [...]

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28/02/2025 - 22:00

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting [...]

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

28/02/2025 - 22:00

Webcast to be held Monday, March 3rd at 8:30 a.m. ET SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel [...]

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

28/02/2025 - 22:00

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the [...]

Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders

28/02/2025 - 22:01

Meeting adjourned to Wednesday, March 5, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ: ACON) (NASDAQ: ACONW), a healthcare [...]

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

28/02/2025 - 22:04

Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% [...]

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

28/02/2025 - 22:04

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]